Vnitr Lek 2011, 57(7-8):603-606

The past, the present and the future of renal replacement therapy

V. Tesař
Klinika nefrologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Vladimír Tesař, DrSc.

The observation that renal failure leads to 'uraemia' through retention of solutes that would otherwise be excreted by healthy kidneys, has been formulated as early as the first half of 19th century. The discovery of osmosis and a colloid membrane facilitated the first testing of dialysis, originally in animals and in the first quarter of 20th century also in humans. In the mid 1940s, dialysis became the method of choice for the treatment of acute renal failure. At the beginning of 1960s, the development of long-term venous access made programmes of chronic haemodialysis possible in many countries. These achievements, together with kidney transplantation, saved or significantly extended life of millions of patients with chronic renal failure. The last 50 years saw a dramatic increase in the number of chronically dialyzed patients; the safety and efficacy of haemodialysis methods improved and effective treatments have been introduced of a number of complications associated with chronic renal failure (e. g. hypertension, anaemia or bone disease). Despite this, mortality of, particularly older chronically dialyzed patients, is very high and their quality of life sometimes low. High cardiovascular mortality, frequently due to chronic heart failure and sudden death (unlike ischemic heart disease in healthy population), is a dominating problem. However, it is difficult to reduce the high cardiovascular morbidity and mortality of haemodialyzed patients. Patient prognosis might probably be improved by more frequent use of convective methods of blood purification and frequent haemodialysis as well as effective management of dyslipidemia. Nevertheless, early diagnosis of patients with chronic renal insufficiency and early management of all general as well as renal failure-specific risk factors in patients with mild to moderate chronic renal insufficiency is essential if the prognosis of haemodialyzed patients is to be improved. Future developments of renal replacement therapies are difficult to predict. The treatment should be individualized; early transplantation, peritoneal or home (frequent) haemodialysis should be performed in younger patients and conservative treatment, in addition to chronic haemodialysis, should be used in older patients. Miniaturization as one of the potential future trends could facilitate the use of portable artificial kidney. Artificial membranes coated with proximal tubule cells and ex vivo kidney cultivation represent another interesting perspective.

Keywords: renal replacement therapy; methods of haemosdialysis; cardiovascular morbidity

Received: April 6, 2011; Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V. The past, the present and the future of renal replacement therapy. Vnitr Lek. 2011;57(7-8):603-606.
Download citation

References

  1. Cameron JS. History of the treatment of renal failure by dialysis. Oxford: Oxford University Press 2002: 1-345. Go to original source...
  2. Matoušovic K, Rychlík I, Dusilová Sulková S. Hereditatis petitio české nefrologie. Praha: Tigis 2009: 1-455.
  3. Herzog CA, Mangrum JM, Passman R et al. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-307. Go to original source... Go to PubMed...
  4. Eknoyan G, Beck GJ, Cheung AK et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019. Go to original source... Go to PubMed...
  5. Locatelli F, Gauly A, Czekalski S et al. Membrane Permeability Outcome (MPO) Study Group. The MPO study: just a European HEMO study or something very different? Blood Purif 2008; 26: 100-104. Go to original source... Go to PubMed...
  6. FHN Group. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300. Go to original source... Go to PubMed...
  7. Davenport A, Gura V, Ronco C et al. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007; 370: 2005-2010. Go to original source... Go to PubMed...
  8. Ding F, Humes HD. The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol 2008; 109: e118-e122. Go to original source... Go to PubMed...
  9. Ross EA, Williams MJ, Hamazaki T et al. Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds. J Am Soc Nephrol 2009; 20: 2338-2347. Go to original source... Go to PubMed...
  10. Yokoo T, Kawamura T. Xenobiotic kidney organogenesis: a new avenue for renal transplantation. J Nephrol 2009; 22: 312-317. Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.